Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
